All Outputs (2)

Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT (2018)
Journal Article
Howard, R., Cort, E., Bradley, R., Harper, E., Kelly, L., Bentham, P., …Gray, R. (2018). Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT. Health Technology Assessment, 22(67), 1-62. https://doi.org/10.3310/hta22670

© Queen's Printer and Controller of HMSO 2018. Background: Very late-onset (aged ≥60 years) schizophrenia-like psychosis (VLOSLP) occurs frequently but no placebo-controlled, randomised trials have assessed the efficacy or risks of antipsychotic trea... Read More about Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT.

Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial (2018)
Journal Article
Howard, R., Cort, E., Bradley, R., Harper, E., Kelly, L., Bentham, P., Ritchie, C., Reeves, S., Fawzi, W., Livingston, G., Sommerlad, A., Oomman, S., Nazir, E., Nilforooshan, R., Barber, R., Fox, C., Macharouthu, A. V., Ramachandra, P., Pattan, V., Sykes, J., …Gray, R. (2018). Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial. Lancet Psychiatry, 5(7), 553-563. https://doi.org/10.1016/S2215-0366%2818%2930141-X

Background

Very late (aged ≥60 years) onset schizophrenia-like psychosis occurs frequently but no placebo-controlled, randomised trials have assessed the efficacy and risks of antipsychotic treatment. We investigated whether low-dose amisulpride (... Read More about Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial.